> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Review Voucher Awarded to Eiger BioPharm
- URL: https://www.fdaweb.com/priority-review-voucher-awarded-to-eiger-biopharm/
- Published: 2020-12-16T12:00:00.000Z
- Updated: 2026-09-14T16:40:30.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148314

*Federal Register* notice: FDA has announced the issuance of a priority review voucher to Eiger BioPharmaceuticals that is related to its rare pediatric disease product NDA for Zokinvy (lonafarnib), indicated in patients 12 months of age and older to reduce the risk of mortality in Hutchinson-Gilford progeria syndrome. To view the notice, click [here](https://public-inspection.federalregister.gov/2020-27778.pdf?ref=fdaweb.com).